The earnings call highlighted AstraZeneca's strong revenue and EPS growth driven by demand for innovative medicines and a successful pipeline. However, challenges remain in specific markets like China and anticipated margin declines. The sentiment is balanced by the company's robust performance in oncology and biopharmaceuticals, alongside pipeline successes.

Company Guidance -

Q3 2025

In the recent call, AstraZeneca provided guidance for the first half of 2025, reporting an 11% growth in total revenue, primarily driven by the demand for innovative medicines. Core EPS saw a 17% increase, reflecting strategic investments in their pipeline. The company achieved 19 regulatory approvals in key regions, with 12 positive Phase III trials announced, including five new molecular entities. Specific growth was noted in oncology and biopharmaceuticals, with rare diseases showing a 7% increase in the second quarter. The KALOS/LOGOS program and BaxHTN trial are highlighted as significant contributors to future growth. AstraZeneca maintains its 2030 ambition, aiming for $80 billion in revenue, with transformative technologies expected to drive growth beyond this target. The company also reiterated its guidance for the year, anticipating high single-digit revenue growth and low double-digit EPS growth.

Strong Revenue and EPS Growth

Total revenue grew by 11% in the first half of 2025, driven by demand for innovative medicines. Core EPS grew 17%, reflecting investment in the pipeline and operational leverage.

Pipeline and Regulatory Success

AstraZeneca achieved 19 regulatory approvals in key regions and announced results of 12 positive Phase III trials, including pivotal data for 5 new molecular entities.

Oncology Segment Performance

Oncology revenue grew 16% to $12 billion in the first half, with notable growth in key brands like Tagrisso (12% growth) and Enhertu (42% growth in Q2).

Emerging Market Growth

Strong performance in emerging markets outside of China, contributing to robust geographical growth.

Biopharmaceuticals and Rare Disease Momentum

Biopharmaceuticals delivered 10% growth to $11.2 billion, with rare disease returning to growth in Q2, up 7%.

AstraZeneca (GB:AZN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:AZN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	1.70 / -	1.557	―	―	―
Jul 29, 2025	2025 (Q2)	1.61 / 1.62	1.482	9.60% (+0.14)	―	―
Apr 29, 2025	2025 (Q1)	1.67 / 1.86	1.542	20.87% (+0.32)	―	―
Feb 06, 2025	2024 (Q4)	1.55 / 1.56	1.086	44.14% (+0.48)	―	―
Nov 12, 2024	2024 (Q3)	1.53 / 1.56	1.295	20.23% (+0.26)	―	―
Jul 25, 2024	2024 (Q2)	1.47 / 1.48	1.61	-7.91% (-0.13)	―	―
Apr 25, 2024	2024 (Q1)	1.43 / 1.54	1.438	7.29% (+0.10)	―	―
Feb 08, 2024	2023 (Q4)	1.09 / 1.09	1.033	5.07% (+0.05)	―	―
Nov 09, 2023	2023 (Q3)	1.26 / 1.30	1.25	3.59% (+0.04)	―	―
Jul 28, 2023	2023 (Q2)	1.48 / 1.61	1.288	25.00% (+0.32)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:AZN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	10715.13p	11080.58p	+3.41%
Apr 29, 2025	10452.96p	10544.32p	+0.87%
Feb 06, 2025	10890.21p	11536.22p	+5.93%
Nov 12, 2024	9773.39p	9778.28p	+0.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AstraZeneca plc (GB:AZN) report earnings?

AstraZeneca plc (GB:AZN) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is AstraZeneca plc (GB:AZN) earnings time?

AstraZeneca plc (GB:AZN) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of AstraZeneca plc stock?

The P/E ratio of AstraZeneca is N/A.

What is GB:AZN EPS forecast?

GB:AZN EPS forecast for the fiscal quarter 2025 (Q3) is 1.7.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing